128 related articles for article (PubMed ID: 15766656)
21. JAK/STAT3-dependent activation of the RalGDS/Ral pathway in M1 mouse myeloid leukemia cells.
Senga T; Iwamoto T; Kitamura T; Miyake Y; Hamaguchi M
J Biol Chem; 2001 Aug; 276(35):32678-81. PubMed ID: 11432872
[TBL] [Abstract][Full Text] [Related]
22. Ras classical effectors: new tales from in silico complexes.
Fuentes G; Valencia A
Trends Biochem Sci; 2009 Nov; 34(11):533-9. PubMed ID: 19801192
[TBL] [Abstract][Full Text] [Related]
23. Identification of Rgl3 as a potential binding partner for Rap-family small G-proteins and profilin II.
Xu J; Shi S; Matsumoto N; Noda M; Kitayama H
Cell Signal; 2007 Jul; 19(7):1575-82. PubMed ID: 17382517
[TBL] [Abstract][Full Text] [Related]
24. Distinct requirements for Ras oncogenesis in human versus mouse cells.
Hamad NM; Elconin JH; Karnoub AE; Bai W; Rich JN; Abraham RT; Der CJ; Counter CM
Genes Dev; 2002 Aug; 16(16):2045-57. PubMed ID: 12183360
[TBL] [Abstract][Full Text] [Related]
25. Conserved electrostatic fields at the Ras-effector interface measured through vibrational Stark effect spectroscopy explain the difference in tilt angle in the Ras binding domains of Raf and RalGDS.
Walker DM; Wang R; Webb LJ
Phys Chem Chem Phys; 2014 Oct; 16(37):20047-60. PubMed ID: 25127074
[TBL] [Abstract][Full Text] [Related]
26. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
Campbell PM; Groehler AL; Lee KM; Ouellette MM; Khazak V; Der CJ
Cancer Res; 2007 Mar; 67(5):2098-106. PubMed ID: 17332339
[TBL] [Abstract][Full Text] [Related]
27. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.
Gupta S; Ramjaun AR; Haiko P; Wang Y; Warne PH; Nicke B; Nye E; Stamp G; Alitalo K; Downward J
Cell; 2007 Jun; 129(5):957-68. PubMed ID: 17540175
[TBL] [Abstract][Full Text] [Related]
28. Crystallization and preliminary crystallographic analysis of the Ras binding domain of RalGDS, a guanine nucleotide dissociation stimulator of the Ral protein.
Huang L; Jancarik J; Kim SH; Hofer F; Martin GS
Acta Crystallogr D Biol Crystallogr; 1996 Sep; 52(Pt 5):1033-5. PubMed ID: 15299618
[TBL] [Abstract][Full Text] [Related]
29. A role for RalGDS and a novel Ras effector in the Ras-mediated inhibition of skeletal myogenesis.
Ramocki MB; White MA; Konieczny SF; Taparowsky EJ
J Biol Chem; 1998 Jul; 273(28):17696-701. PubMed ID: 9651367
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine phosphorylation of RalGDS by c-Met receptor blocks its interaction with Ras.
Wong R; Feig LA
Biochem Biophys Res Commun; 2016 Nov; 480(3):468-473. PubMed ID: 27773821
[TBL] [Abstract][Full Text] [Related]
31. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone.
Yin J; Pollock C; Tracy K; Chock M; Martin P; Oberst M; Kelly K
Mol Cell Biol; 2007 Nov; 27(21):7538-50. PubMed ID: 17709381
[TBL] [Abstract][Full Text] [Related]
32. Ras interaction with RalGDS effector targets.
Koyama S; Kikuchi A
Methods Enzymol; 2001; 332():127-38. PubMed ID: 11305091
[No Abstract] [Full Text] [Related]
33. Structural basis for the interaction of Ras with RalGDS.
Huang L; Hofer F; Martin GS; Kim SH
Nat Struct Biol; 1998 Jun; 5(6):422-6. PubMed ID: 9628477
[TBL] [Abstract][Full Text] [Related]
34. Stopping ras in its tracks.
Der CJ; Van Dyke T
Cell; 2007 Jun; 129(5):855-7. PubMed ID: 17540164
[TBL] [Abstract][Full Text] [Related]
35. The application of abstract topology to RAS-related signal transduction pathways.
Cárdenas-García M; Lagunez Otero J; Korneev NA
In Silico Biol; 2002; 2(4):453-60. PubMed ID: 12611625
[TBL] [Abstract][Full Text] [Related]
36. Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling.
Repasky GA; Zhou Y; Morita S; Der CJ
Mol Carcinog; 2007 Dec; 46(12):958-70. PubMed ID: 17477350
[TBL] [Abstract][Full Text] [Related]
37. Activation of Ras proteins by Ras guanine nucleotide releasing protein family members.
Lambert QT; Reuther GW
Methods Enzymol; 2006; 407():82-98. PubMed ID: 16757316
[TBL] [Abstract][Full Text] [Related]
38. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
Feng W; Brown RE; Trung CD; Li W; Wang L; Khoury T; Alrawi S; Yao J; Xia K; Tan D
Ann Clin Lab Sci; 2008; 38(3):195-209. PubMed ID: 18715846
[TBL] [Abstract][Full Text] [Related]
39. Ras signaling and therapies.
Young A; Lyons J; Miller AL; Phan VT; Alarcón IR; McCormick F
Adv Cancer Res; 2009; 102():1-17. PubMed ID: 19595305
[TBL] [Abstract][Full Text] [Related]
40. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.
Lim KH; Counter CM
Cancer Cell; 2005 Nov; 8(5):381-92. PubMed ID: 16286246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
